Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Bacterium or component thereof or substance produced by said...
Reexamination Certificate
2006-07-21
2009-10-27
Navarro, Mark (Department: 1645)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Bacterium or component thereof or substance produced by said...
C424S239100, C424S247100
Reexamination Certificate
active
07608275
ABSTRACT:
Methods and apparatus are provided for applying an fragment of a neurotoxin such as the active light chain (LC) of the botulinum toxin (BoNT), such as one of the serotype A, B, C, D, E, F or G botulinum toxins, via permeabilization of targeted cell membranes to enable translocation of the botulinum neurotoxin light chain (BoNT-LC) molecule across the targeted cell membrane to the cell cytosol where a therapeutic response is produced in a mammalian system. The methods and apparatus include use of catheter based delivery systems, non-invasive delivery systems, and transdermal delivery systems.
REFERENCES:
patent: 4767402 (1988-08-01), Kost et al.
patent: 5286254 (1994-02-01), Shapland et al.
patent: 5766605 (1998-06-01), Sanders et al.
patent: 5820589 (1998-10-01), Torgerson et al.
patent: 5964223 (1999-10-01), Baran
patent: 6063768 (2000-05-01), First
patent: 6139845 (2000-10-01), Donovan
patent: 6265379 (2001-07-01), Donovan
patent: 6358926 (2002-03-01), Donovan
patent: 6361554 (2002-03-01), Brisken
patent: 6447785 (2002-09-01), Donovan
patent: 6448231 (2002-09-01), Graham
patent: 6464680 (2002-10-01), Brisken et al.
patent: 6526976 (2003-03-01), Baran
patent: 6601581 (2003-08-01), Babaev
patent: 6620415 (2003-09-01), Donovan
patent: 6623742 (2003-09-01), Voet
patent: 6626855 (2003-09-01), Weng et al.
patent: 6632440 (2003-10-01), Quinn et al.
patent: 6645496 (2003-11-01), Aoki et al.
patent: 6649161 (2003-11-01), Donovan
patent: 6719694 (2004-04-01), Weng et al.
patent: 6740321 (2004-05-01), Donovan
patent: 6767544 (2004-07-01), Brooks et al.
patent: 6773711 (2004-08-01), Voet et al.
patent: 6776991 (2004-08-01), Naumann
patent: 6827931 (2004-12-01), Donovan
patent: 6838434 (2005-01-01), Voet
patent: 6841156 (2005-01-01), Aoki et al.
patent: 6843998 (2005-01-01), Steward et al.
patent: 6847849 (2005-01-01), Mamo et al.
patent: 6861058 (2005-03-01), Aoki et al.
patent: 6872397 (2005-03-01), Aoki et al.
patent: 2001/0044596 (2001-11-01), Jaafar
patent: 2002/0198512 (2002-12-01), Seward
patent: 2003/0050591 (2003-03-01), McHale
patent: 2003/0202990 (2003-10-01), Donovan et al.
patent: 2003/0211121 (2003-11-01), Donovan
patent: 2004/0009180 (2004-01-01), Donovan
patent: 2004/0010290 (2004-01-01), Schroeppel et al.
patent: 2004/0091880 (2004-05-01), Wiebusch et al.
patent: 2004/0142005 (2004-07-01), Brooks et al.
patent: 2004/0175399 (2004-09-01), Schiffman
patent: 2004/0213813 (2004-10-01), Ackerman
patent: 2004/0213814 (2004-10-01), Ackerman
patent: 2004/0226556 (2004-11-01), Deem et al.
patent: 2004/0253274 (2004-12-01), Voet
patent: WO 2004/101028 (2004-11-01), None
Kreitman, R. J., Taming ricin, 2003, Nature Biotechnology, 21:372-4.
Buzzi, S., Diphteria toxin treatment of human advanced cancer, 1982, Cancer research, 42:2054-8.
Paiva et al, Light chain of botulinum neurotoxin is active in mammalian motor nerve terminals when delivered via liposomes, 1990, FEBS, vol. 277, p. 171-4.
Sundaram et al, An experimental and theoretical analysis of ultrasound-induced permeabilization of cell membranes, 2003, Biophysical Journal, vol. 84, p. 3087-101.
Ahnert-Hilger et al., “Introduction of Macromolecules into Bovine Adrenal-Medullary Chromaffin Cells and Rat Pheochromacytoma Cells (PC12) by Permeabilization with Streptolysin-Oinhibitory Effect of Tetanus Toxin on Catecholamine Secretion,”J. Neurochem. Jun. 1989; 52(6):1751-1758.
Bigalke et al., “Clostridia Toxins”,Handbook of Experimental Pharmacology(Aktries, K., and Just, I., eds) 2000, 145:407-443, Springer Verlag, Berlin, Heidelberg.
Bittner et al., “Isolated Light Chains of Botulinum Neurotoxins Inhibit Exocytosis. Studies in Digitonin-Permeabilized Chromaffin Cells.”J Biol ChemJun. 25, 1989;264(18):10354-10360.
Chaddock et al “Expression and Purification of Catalytically Active, Non-Toxic Endopeptidase Derivatives of Clostridium Botulinum Toxin Type A,”Protein Expression and Purification, Jul. 2002, 25(2): 219-228.
Chang, “Cell Poration and Cell Fusion Using an Oscillating Electric Field,”Biophys J. Oct. 1989; 56(4): 641-652.
Guzman et al., “Bioeffects Caused by Changes in Acuostic Cavitation Bubble Density and Cell Concentration: A Unified Explanation Based on Cell-to-Bubble Ratio and Blast Radius,”Ultrasound in Med. &Biol., 2003, 29(8): 1211-1222.
Kistner et al, “Reductive Cleavage of Tetanus Toxin and Botulinum Neurotoxin A by the Thioredoxin System from Brain. Evidence for Two Redox Isomers of Tetanus Toxin,”Naunyn Schmiedebergs Arch Pharmacol. Feb 1992; 345(2)227-34.
Simpson et al., “Isolation and Characterization of the Botulinum Neurotoxins,”Methods Enzymol. 1988; 165:76-85.
Weaver, “Electroporation: A General Phenomenon for Manipulating Cells and Tissues,”Cell Biochem. Apr. 1993; 51(4):426-35.
RAJ, Editorial,Pain Practice, 4(1S):S1-S3.
Deem Mark E.
Gifford Hanson
Grainger, Esq. Jeffry
Navarro Mark
The Foundry, LLC
Townsend and Townsend / and Crew LLP
LandOfFree
Systems and methods for delivery of a therapeutic agent does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Systems and methods for delivery of a therapeutic agent, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Systems and methods for delivery of a therapeutic agent will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4079394